Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Laboratorios Farmaceuticos Rovi Cash-to-Debt?
Laboratorios Farmaceuticos RoviLABFF 99 Cash-to-Debt is 1.19 as of Jun. 2026, which is 27% above its 10-year median of 0.94. GuruFocus rates LABFF with a GF Score™ of 99/100 and a GF Value™ of $85.89 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 950 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 53.68% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Laboratorios Farmaceuticos Rovi's cash to debt ratio for the quarter that ended in Jun. 2026 was 1.19.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Laboratorios Farmaceuticos Rovicould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Cash-to-Debt or its related term are showing as below:
LABFF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14 Med: 0.94 Max: 2.79
Current: 1.19
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest Cash to Debt Ratio was 2.79. The lowest was 0.14. And the median was 0.94.
LABFF's Cash-to-Debt is ranked better than 53.68% of 950
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs LABFF: 1.19
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Laboratorios Farmaceuticos Rovi Cash-to-Debt Related Terms
Laboratorios Farmaceuticos Rovi Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (LABFF) has a Cash-to-Debt of 1.19 as of Jun. 2026. This is 27% above median its historical median of 0.94. Over the past decade, Laboratorios Farmaceuticos Rovi's Cash-to-Debt has ranged from 0.14 to 2.79. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #440 out of 950 companies in the Drug Manufacturers industry, placing it in the top 46.3%.
Is Laboratorios Farmaceuticos Rovi's Cash-to-Debt too high?
Laboratorios Farmaceuticos Rovi's current Cash-to-Debt of 1.19 is 27% above median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 2.79. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Laboratorios Farmaceuticos Rovi's value of 1.19 is 21.4% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #440 out of 950 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #440 out of 950 companies for Cash-to-Debt. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. The industry median Cash-to-Debt is 0.98. Laboratorios Farmaceuticos Rovi's value of 1.19 is 21.4% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Cash-to-Debt has ranged from 0.14 to 2.79 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 0.98, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Cash-to-Debt of 1.19 is 21.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Cash-to-Debt is 1.19, which is 27% above median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (LABFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $85.89, compared to a current price of $67.17 — trading 21.8% below its estimated fair value. The current Cash-to-Debt is 1.19, which is 27% above median its 10-year median of 0.94 and 21.4% above the Drug Manufacturers industry median of 0.98. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Cash-to-Debt is 1.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be undervalued.
The current stock price of $67.17 is trading 21.8% below its estimated GF Value™ of $85.89.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Undervalued.
Key valuation signals for LABFF:
Cash-to-Debt: 1.19 (27% above median its 10-year median of 0.94)
GF Value™: $85.89 vs. price of $67.17 (21.8% below fair value)
Industry Position: 21.4% above the Drug Manufacturers median (#440 of 950)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
99GF Score
Get the complete analysis for LABFF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
